German leading optical retail chain selling eyeglasses, contact lenses and hearing aids across Europe.
German leading optical retail chain selling eyeglasses, contact lenses and hearing aids across Europe.
Sells glasses and lenses directly from its own stores, partly from its own factory and direct sourcing, which lets it price low and win volume in prescription eyewear. Hearing aids are fitted and sold in the same shops. The founding Fielmann family keeps the majority.
In one line: A German Warby Parker/LensCrafters hybrid, but much larger scale in Europe.
Moat: narrow (scale, brand, distribution). Largest European optical retail network with low-cost, vertically integrated model, but a competitive, mature retail category.
Headquarters: Hamburg, Germany · Founded: 1972 · Employees: 23,832
Size Fielmann (FIE.DE) is a Germany Health Care company (Medical Specialties) with a market value of $3.92B, the 79th largest of 198 Germany companies the cockpit tracks. Shares closed at €42.55 on 18 Nov 2026.
Performance Over six months the shares fell 3.1%, against +23.2% for the median peer and -0.9% for the Germany market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue grew 2.9% over the last twelve months (peer median +8.7%); the operating margin is 14.0% (peer median 12.0%).
Valuation It trades at 17.1× forward earnings against a peer median of 22.8× (5th cheapest of 19).
Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -17 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 8.4 points above its cost of capital (5.5% WACC).
Next results Next results expected around 12 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €2.47B | €2.44B | €2.27B | €1.97B | €1.76B |
| Revenue growth | — | +7% | +15% | +12% | — |
| Gross profit | €702M | €656M | €563M | €478M | €504M |
| EBITDA | €576M | €553M | €468M | €384M | €413M |
| Net income | €212M | €204M | €152M | €125M | €104M |
| Free cash flow | €304M | €352M | €304M | €185M | €155M |
| Capital expenditure | €120M | €116M | €82.7M | €86.8M | €85.4M |
| Total debt | n/a | €884M | €882M | €652M | €566M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Fielmann FIE.DE | $3.92B | -3% | +3% | 14% | 17.1× | -5.5% |
| EssilorLuxottica EL.PA | $91.9B | +5% | +8% | 12% | 24.8× | 18.4% |
| Warby Parker WRBY | $3.50B | +15% | +10% | 0% | 56.2× | n/a |
| Amplifon AMP.MI | $3.39B | +8% | 0% | 10% | 17.0× | 6.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | FIE.DE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +9.7% | +3.5% | 8th highest of 21 |
| 6-month return | -3.1% | +23.2% | 5th lowest of 21 |
| Distance from 52-week high | -11.3% | -22.1% | 5th highest of 21 |
| Revenue growth (TTM) | +2.9% | +8.7% | 6th lowest of 21 |
| Operating margin | 14.0% | 12.0% | 6th highest of 20 |
| Forward P/E | 17.1× | 22.8× | 5th cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | -5.5% | 12.7% | 2nd least demanding of 16 |
| Growth delivered (Del g) | +11.3% | +8.1% | 5th highest of 16 |
| Hurdle (Req g minus delivered) | -16.7 pp | +1.0 pp | 2nd least demanding of 16 |
| ROIC minus cost of capital | +8.4 pp | -0.8 pp | highest of 19 |
| EV / EBITDA | 7.3× | 13.1× | 2nd cheapest of 11 |
| Net debt / EBITDA | 1.1× | 0.1× | 5th most indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Fielmann FIE.DE | Germany | $3.92B | -3% | +3% | 14% | 17.1× | -5.5% | +11.3% |
| CareDx CDNA | United States | $3.91B | +252% | +39% | 1% | 50.6× | n/a | n/a |
| Andon Health 002432.SZ | China | $3.86B | -24% | -30% | -26% | 16.1× | -6.6% | -7.4% |
| Envista NVST | United States | $3.81B | 0% | +10% | 12% | 14.7× | 4.8% | +7.1% |
| SCHOTT Pharma AG & Co. KGaA 1SXP.DE | Germany | $3.73B | +32% | +4% | 15% | 23.0× | 12.7% | +11.0% |
| Jiangsu Yuyue Medical Equipment & Supply 002223.SZ | China | $4.18B | -3% | -1% | 13% | 20.0× | 4.9% | +3.4% |
| Stevanato STVN | United States | $4.19B | -13% | +12% | 18% | 22.5× | 13.1% | +12.1% |
| Shandong Weigao Blood Purification Products 603014.SS | China | $3.63B | -1% | +4% | n/a | 20.4× | -1.2% | +8.1% |
| Tecan TECN.SW | Switzerland | $3.60B | +59% | -4% | 1% | 35.5× | 45.4% | +3.8% |
| Sumitomo Bakelite 4203.T | Japan | $3.50B | +7% | +15% | 13% | 15.9× | 8.6% | +8.9% |
| Ambu A/S AMBU-B.CO | Denmark | $3.47B | +31% | +7% | 13% | 28.8× | 10.0% | +10.0% |
| ICU Medical ICUI | United States | $4.46B | +38% | -6% | 8% | 19.4× | 18.9% | +11.9% |
| Axogen AXGN | United States | $3.40B | +33% | +24% | -5% | 87.3× | 52.6% | +14.9% |
| Pulse Biosciences PLSE | United States | $3.37B | +76% | +1,637% | -5,821% | n/a | n/a | n/a |
| Autobio Diagnostics 603658.SS | China | $3.36B | +16% | +3% | 25% | 20.3× | -0.4% | +7.2% |
| TransMedics TMDX | United States | $3.35B | +42% | +28% | 12% | 43.4× | 38.4% | +88.2% |
| GRAIL GRAL | United States | $4.59B | +67% | +17% | -332% | n/a | n/a | n/a |
| iRay Technology 688301.SS | China | $3.31B | -30% | +58% | 24% | 25.7× | n/a | n/a |
| Sotera Health SHC | United States | $4.65B | +5% | +7% | 37% | 15.7× | 14.4% | +7.3% |
| Zhende Medical 603301.SS | China | $3.26B | -10% | +8% | 7% | 42.5× | 22.9% | -16.1% |
| MiniMed MMED | United States | $4.78B | +46% | +14% | 14% | 26.3× | n/a | n/a |